People living with type 1 diabetes (T1D; approximately 300,000 in Canada) need to be administered subcutaneous insulin to maintain stable blood glucose (BG) levels and prevent long-term complications [1,2]. The gene discussed is INS; the disease is type 1 diabetes mellitus.